Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8384543 | 0.84 | NPSR1 (0.53) | MAPTALDH1A1NPSR1RXFP1KDM4E | |
| SCHEMBL4747831 | 0.81 | NPSR1 (0.51) | MAPTALDH1A1NPSR1RXFP1KDM4E | |
| SCHEMBL4787361 | 0.80 | ALDH1A1 (0.47) | MAPTALDH1A1NPSR1RXFP1KDM4E | |
| SCHEMBL4786404 | 0.79 | ALDH1A1 (0.47) | MAPTALDH1A1NPSR1RXFP1KDM4E | |
| SCHEMBL4748211 | 0.78 | NPSR1 (0.41) | MAPTALDH1A1NPSR1RXFP1KDM4E | |
| SCHEMBL7900197 | 0.78 | SYK (0.40) | MAPTALDH1A1NPSR1RXFP1KDM4E | |
| SCHEMBL8379706 | 0.77 | JUN (0.52) | MAPTALDH1A1NPSR1RXFP1KDM4E | |
| SCHEMBL8383001 | 0.76 | NPSR1 (0.44) | MAPTALDH1A1NPSR1RXFP1KDM4E | |
| SCHEMBL14069780 | 0.75 | ALDH1A1 (0.42) | MAPTALDH1A1NPSR1RXFP1KDM4E | |
| SCHEMBL6441875 | 0.73 | ADORA1 (0.76) | MAPTALDH1A1NPSR1RXFP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008110891-A2 | NEW HETEROCYCLIC COMPOUNDS | ORCHID RESEARCH LABORATORIES LIMITED, (IN) | 2008-09-18 | — | — | WO | claimed |
| US-20080221103-A1 | New heterocyclic compounds | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2008-09-11 | — | — | US | claimed |
| WO-2008110891-A2 | NEW HETEROCYCLIC COMPOUNDS | ORCHID RESEARCH LABORATORIES LIMITED, (IN) | 2008-09-18 | — | — | WO | disclosed |
| US-20080221103-A1 | New heterocyclic compounds | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2008-09-11 | — | — | US | disclosed |
| US-20080221103-A1 | New heterocyclic compounds | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221103-A1 | New heterocyclic compounds | LOXL4, CXCR4, LTC4S | MAPT 699/4885ALDH1A1 825/4885NPSR1 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.